Melatonin and sleep disorders associated with intellectual disability: A clinical review

Journal of Intellectual Disability Research

Volumn 51, Issue 1, 2007, Pages 2-13

  Sajith, S G ^a   Clarke, D ^a  

^a Lea Castle Centre   (United Kingdom)

Author keywords

Adverse reactions; Drug interactions; Efficacy; Intellectual disability; Melatonin; Sleep disorder

Indexed keywords

ACETYLSALICYLIC ACID; ANTIHISTAMINIC AGENT; ANTIINFLAMMATORY AGENT; BENZODIAZEPINE; CHLORPROMAZINE; CORTICOSTEROID; FLUVOXAMINE; MELATONIN; NIFEDIPINE; PLACEBO; SERTRALINE; WARFARIN; ZALEPLON; ZOLPIDEM; ZOPICLONE;

AGITATION; AMNESIA; ASTHMA; ATAXIA; AUTOIMMUNE HEPATITIS; BLOOD PRESSURE; CIRCADIAN RHYTHM; CLINICAL TRIAL; CONFUSION; COORDINATION DISORDER; DAYTIME SOMNOLENCE; DEPRESSION; DISEASE EXACERBATION; DIZZINESS; DROWSINESS; DRUG ANTAGONISM; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERANCE; DYSPHORIA; ENDOCRINE FUNCTION; EPILEPSY; HORMONE BLOOD LEVEL; HORMONE METABOLISM; HORMONE RELEASE; HORMONE SYNTHESIS; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INSOMNIA; INTELLECTUAL IMPAIRMENT; META ANALYSIS; NAUSEA; NEUROLOGIC DISEASE; OPTIC NERVE DISEASE; PARESTHESIA; PSYCHOSIS; REVIEW; SEDATION; SEIZURE; SEXUAL FUNCTION; SIDE EFFECT; SLEEP DISORDER; SLEEP INDUCTION; SLEEP WAKING CYCLE; SYSTEMATIC REVIEW; URINE RETENTION; XEROSTOMIA;

ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; CLINICAL TRIALS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; HUMANS; MELATONIN; MENTAL RETARDATION; SLEEP DISORDERS, CIRCADIAN RHYTHM; TREATMENT OUTCOME;

EID: 33845344332     PISSN: 09642633     EISSN: 13652788     Source Type: Journal    
DOI: 10.1111/j.1365-2788.2006.00893.x     Document Type: Review

References (87)

1. Acuna-Castroviejo D., Escames G., Molina Carballo A., Arauzo M. & Montes R. (1995) Cell protective role of melatonin in the brain. Journal of Pineal Research 19, 57-63.
2. Aldhous M., Franey C., Wright J. & Arendt J. (1985) Plasma concentrations of melatonin in man following oral absorption of different preparations. British Journal of Clinical Pharmacology 19, 517-21.
3. Arangino S., Cagnacci A., Angiolucci M., Vacca A. M., Longu G., Volpe A. & Melis G. B. (1999) Effects of melatonin on vascular reactivity, catecholamine levels, and blood pressure in healthy men. American Journal of Cardiology 83, 1417-19.
4. Armour D. & Paton C. (2004) Melatonin in the treatment of insomnia in children and adolescents. Psychiatric Bulletin 28, 222-4.
5. Attanasio A., Borrelli P. & Gupta D. (1985) Circadian rhythms in serum melatonin from infancy to adolescence. Journal of Clinical Endocrinology and Metabolism 61, 388-90.
6. von Bahr C., Ursing C., Yasui N., Tybring G., Bertilsson L. & Rojdmark S. (2000) Fluvoxamine but not citalopram increases serum melatonin in healthy subjects - an indication that cytochrome P450 CYP1A2 and CYP2C19 hydroxylate melatonin. European Journal of Clinical Pharmacology 56, 123-7.
7. Bramble D. & Feehan C. (2005) Psychiatrists' use of melatonin with children. Child and Adolescent Mental Health 10, 145-9.
8. Brismar K., Hylander B., Eliasson K. & Rossner S. (1988) Melatonin secretion related to side-effects of beta- blockers from the central nervous system. Acta Medica Scandinavica 223, 525-30.
9. Brylewski J. & Wiggs L. (1999) Sleep problems and daytime challenging behaviour in a community-based sample of adults with intellectual disability. Journal of Intellectual Disability Research 43, 504-12.
10. Brzezinski A., Vangel M. G., Wurtman R. J., Norrie G., Zhdanova I., Ben-Shushan A. & Ford I. (2005) Effects of exogenous melatonin on sleep: A meta-analysis. Sleep Medicine Reviews 9, 41-50.
11. Buscemi N., Vandermeer B., Hooton N., Pandya R., Tjosvold L., Hartling L., Vohra S., Klassen T. P. & Baker G. (2006) Efficacy and safety of exogenous melatonin for secondary sleep disorders and sleep disorders accompanying sleep restriction: Meta-analysis. British Medical Journal 332, 385-93.
12. Cagnacci A., Elliott J. A. & Yen S. S. C. (1992) Melatonin: A major regulator of the circadian rhythm of core temperature in humans. Journal of Clinical Endocrinology and Metabolism 75, 447-52.
13. Cagnacci A., Arangino S., Renzi A., Paoletti A. M., Melis G. B., Cagnacci P. & Volpe A. (2001) Influence of melatonin administration on glucose tolerance and insulin sensitivity of postmenopausal women. Clinical Endocrinology 54, 339-46.
14. Cajochen C., Krauchi K., von Arx M. A., Mori D., Graw P. & Wirz-Justice A. (1996) Daytime melatonin administration enhances sleepiness and theta/alpha activity in the waking EEG. Neuroscience Letter 207, 209-13.
15. Calvo J. R., Guerrero J. M., Osuna C., Molinero P. & Carrillo-Vico A. (2002) Melatonin triggers Crohn's disease symptoms. Journal of Pineal Research 32, 277-8.
16. Camfield P., Gordon K., Dooley J. & Camfield C. (1996) Melatonin appears ineffective in children with intellectual deficits and fragmented sleep: Six 'N of 1' trials. Journal of Child Neurology 11, 341-3.
17. Campos F. L., da Silva-Junior F. P., de Bruin V. M. S. & de Bruin P. F. C. (2004) Melatonin improves sleep in asthma: A randomized, double-blind, placebo-controlled study. American Journal of Respiratory and Critical Care Medicine 170, 947-51.
18. Cardinali D. P., Del Zar M. M. & Vacas M. I. (1993) The effects of melatonin in human platelets. Acta Physiologica, Pharmacologica et Therapeutica Latinoamericana 43, 1-13.
19. Carman J. S., Post R. M., Buswell R. & Goodwin F. K. (1976) Negative effects of melatonin on depression. American Journal of Psychiatry 133, 1181-6.
20. Cavallo A. (1992) Plasma melatonin rhythm in normal puberty: interactions of age and pubertal stages. Neuroendocrinology 55, 372-9.
21. Cavallo A. & Ritschel W. A. (1996) Pharmacokinetics of melatonin in human sexual maturation. Journal of Clinical Endocrinology and Metabolism 81, 1882-6.
22. Coppola G., Iervolino G., Mastrosimone M., La Torre G., Ruiu F. & Pascotto A. (2004) Melatonin in wake-sleep disorders in children, adolescents and young adults with mental retardation with or without epilepsy: A double-blind, cross-over, placebo-controlled trial. Brain and Development 26, 373-6.
23. De Leersnyder H., de Blois M. C., Claustrat B., Romana S., Albrecht U., von Kleist-Retzow J. C., Delobel B., Viot G., Lyonnet S., Vekemans M. & Munnich A. (2001) Inversion of the circadian rhythm of melatonin in the Smith-Magenis syndrome. Journal of Pediatrics 139, 111-16.
24. DeMuro R. L., Nafziger A. N., Blask D. E., Menhinick A. M. & Bertino J. S., Jr (2000) The absolute bioavailability of oral melatonin. Journal of Clinical Pharmacology 40, 781-4.
25. Dodge N. N. & Wilson G. A. (2001) Melatonin for treatment of sleep disorders in children with developmental disabilities. Journal of Child Neurology 16, 581-4.
26. Dolberg O. T., Hirschmann S. & Grunhaus L. (1998) Melatonin for the treatment of sleep disturbances in major depressive disorder. American Journal of Psychiatry 155, 1119-21.
27. Dubocovich M. L., Rivera-Bermudez M. A., Gerdin M. J. & Masana M. I. (2003) Molecular pharmacology, regulation and function of mammalian melatonin receptors. Frontiers in Bioscience 8, d1093-108.
28. Ehrenkranz J. R., Tamarkin L., Comite F., Johnsonbaugh R. E., Bybee D. E., Loriaux D. L. & Cutler G. B., Jr (1982) Daily rhythm of plasma melatonin in normal and precocious puberty. Journal of Clinical Endocrinology and Metabolism 55, 307-10.
29. Ekman A. C., Leppaluoto. J., Huttunen P., Aranko K. & Vakkuri O. (1993) Ethanol inhibits melatonin secretion in healthy volunteers in a dose-dependent randomized double blind cross-over study. Journal of Clinical Endocrinology and Metabolism 77, 780-3.
30. Force R. W., Hansen L. & Badell M. (1997) Psychotic episode after melatonin. Annals of Pharmacotherapy 31, 1408.
31. Forsling M. L., Wheeler M. J. & Williams A. J. (1999) The effect of melatonin administration on pituitary hormone secretion in man. Clinical Endocrinology 51, 637-42.
32. Gibb J. W., Bush L. & Hanson G. R. (1997) Exacerbation of methamphetamine-induced neurochemical deficits by melatonin. Journal of Pharmacology and Experimental Therapeutics 283, 630-5.
33. Gunning M. J. & Espie C. A. (2003) Psychological treatment of reported sleep disorder in adults with intellectual disability using a multiple baseline design. Journal of Intellectual Disability Research 47, 191-202.
34. Haimov I., Laudon M., Zisapel N., Souroujon M., Nof D., Shlitner A., Herer P., Tzischinsky O. & Lavie P. (1994) Sleep disorders and melatonin rhythms in elderly people. British Medical Journal 309, 167.
35. Hartter S., Grozinger M., Weigmann H., Roschke J. & Hiemke C. (2000) Increased bioavailability of oral melatonin after fluvoxamine coadministration. Clinical Pharmacology and Therapeutics 67, 1-6.
36. Hartter S., Wang X., Weigmann H., Friedberg T., Arand M., Oesch F. & Hiemke C. (2001) Differential effects of fluvoxamine and other antidepressants on the biotransformation of melatonin. Journal of Clinical Psychopharmacology 21, 167-74.
37. Herxheimer A. (2006) Does melatonin help people sleep? British Medical Journal 332, 373-4.
38. Hong Y. G. & Riegler J. L. (1997) Is melatonin associated with the development of autoimmune hepatitis? Journal of Clinical Gastroenterology 25, 376-8.
39. Jahnke G., Marr M., Myers C., Wilson R., Travlos G. & Price C. (1999) Maternal and developmental toxicity evaluation of melatonin administered orally to pregnant Sprague-Dawley rats. Toxicological Sciences 50, 271-9.
40. Jan M. M. (2000) Melatonin for the treatment of handicapped children with severe sleep disorders. Pediatric Neurology 23, 229-32.
41. Jan J. E., Espezel H. & Appleton R. E. (1994) The treatment of sleep disorders with melatonin. Developmental Medicine and Child Neurology 36, 97-107.
42. Jan J. E., Hamilton D., Seward N., Fast D. K., Freeman R. D. & Laudon M. (2000) Clinical trials of controlled-release melatonin in children with sleep-wake cycle disorders. Journal of Pineal Research 29, 34-9.
43. Kayumov L., Brown G., Jindal R., Buttoo K. & Shapiro C. M. (2001) A randomized, double-blind, placebo- controlled crossover study of the effect of exogenous melatonin on delayed sleep phase syndrome. Psychosomatic Medicine 63, 40-8.
44. Laforce R., Rigozzi K., Paganetti M., Guainazzi P. & Calderari G. (1999) Aspects of melatonin manufacturing and requirements for a reliable active component. Biological Signals and Receptors 8, 143-6.
45. Lavie P. (1997) Melatonin: Role in gating nocturnal rise in sleep propensity. Journal of Biological Rhythms 12, 657-65.
46. Lehman N. L. & Johnson L. N. (1999) Toxic optic neuropathy after concomitant use of melatonin, zoloft, and a high-protein diet. Journal of Neuro-Ophthalmology 19, 232-4.
47. Lewy A. J., Ahmed S., Jackson J. M. & Sack R. L. (1992) Melatonin shifts human circadian rhythms according to a phase-response curve. Chronobiology International 9, 380-92.
48. Lewy A. J., Bauer V. K., Cutler N. L. & Sack R. L. (1998) Melatonin treatment of winter depression: A pilot study. Psychiatry Research 77, 57-61.
49. Luboshitzky R., Lavi S., Thuma I. & Lavie P. (1995) Increased nocturnal melatonin secretion in male patients with hypogonadotropic hypogonadism and delayed puberty. Journal of Clinical Endocrinology and Metabolism 80, 2144-8.
50. Luboshitzky R., Shen-Orr Z., Nave R., Lavi S. & Lavie P. (2002) Melatonin administration alters semen quality in healthy men. Journal of Andrology 23, 572-8.
51. Lusardi P., Piazza E. & Fogari R. (2000) Cardiovascular effects of melatonin in hypertensive patients well controlled by nifedipine: A 24-hour study. British Journal of Clinical Pharmacology 49, 423-7.
52. McArthur A. J. & Budden S. S. (1998) Sleep dysfunction in Rett syndrome: A trial of exogenous melatonin treatment. Developmental Medicine and Child Neurology 40, 186-92.
53. McIntyre I. M., Norman T. R., Burrows G. D. & Armstrong S. M. (1993) Alternations to plasma melatonin and cortisol after evening alprazolam administration in humans. Chronobiology International 10, 205-13.
54. Millan M. J., Gobert A., Lejeune F., Dekeyne A., Newman-Tancredi A., Pasteau V., Rivet J. M. & Cussac D. (2003) The novel melatonin agonist agomelatine (S20098) is an antagonist at 5-hydroxytryptamine2C receptors, blockade of which enhances the activity of frontocortical dopaminergic and adrenergic pathways. Journal of Pharmacology and Experimental Therapeutics 306, 954-64.
55. Miyamoto A., Oki J., Takahashi S. & Okuno A. (1999) Serum melatonin kinetics and long-term melatonin treatment for sleep disorders in Rett syndrome. Brain and Development 21, 59-62.
56. Molina-Carballo A., Munoz-Hoyos A., Reiter R. J., Sanchez-Forte M., Moreno-Madrid F., Rufo-Campos M., Molina-Font J. A. & Acuna-Castroviejo D. (1997) Utility of high doses of melatonin as adjunctive anticonvulsant therapy in a child with severe myoclonic epilepsy: Two years' experience. Journal of Pineal Research 23, 97-105.
57. Murphy P. J., Myers B. L. & Badia P. (1996) Nonsteroidal anti-inflammatory drugs alter body temperature and suppress melatonin in humans. Physiology and Behavior 59, 133-9.
58. O'Callaghan F. J., Clarke A. A., Hancock E., Hunt A. & Osborne J. P. (1999) Use of melatonin to treat sleep disorders in tuberous sclerosis. Developmental Medicine and Child Neurology 41, 123-6.
59. Paavonen E. J., Nieminen-Von Wendt T., Vanhala R., Aronen E. T. & Von Wendt L. (2003) Effectiveness of melatonin in the treatment of sleep disturbances in children with Asperger disorder. Journal of Child and Adolescent Psychopharmacology 13, 83-95.
60. Palm L., Blennow G. & Wetterberg L. (1997) Long-term melatonin treatment in blind children and young adults with circadian sleep-wake disturbances. Developmental Medicine and Child Neurology 39, 319-25.
61. Peled N., Shorer Z., Peled E. & Pillar G. (2001) Melatonin effect on seizures in children with severe neurologic deficit disorders. Epilepsia 42, 1208-10.
62. Phillips L. & Appleton R. E. (2004) Systematic review of melatonin treatment in children with neurodevelopmental disabilities and sleep impairment. Developmental Medicine and Child Neurology 46, 771-5.
63. Quine L. (1991) Sleep problems in children with mental handicap. Journal of Mental Deficiency Research 35, 269-90.
64. Ritvo E., Ritvo R., Yuwiler A. & Brother A. (1993) Elevated daytime melatonin concentrations in autism: A pilot study. European Child and Adolescent Psychiatry 2, 75-8.
65. Ross C., Davies P. & Whitehouse W. (2002) Melatonin treatment for sleep disorders in children with neurodevelopmental disorders: An observational study. Developmental Medicine and Child Neurology 44, 339-44.
66. Samples J. R., Krause G. & Lewy A. J. (1988) Effect of melatonin on intraocular pressure. Current Eye Research 7, 649-53.
67. Seabra M. L., Bignotto M., Pinto L. R., Jr & Tufik S. (2000) Randomized, double-blind clinical trial, controlled with placebo, of the toxicology of chronic melatonin treatment. Journal of Pineal Research 29, 193-200.
68. Sheldon S. H. (1998) Pro-convulsant effects of oral melatonin in neurologically disabled children. Lancet 351, 1254.
69. Simonneaux V. & Ribelayga C. (2003) Generation of the melatonin endocrine message in mammals: A review of the complex regulation of melatonin synthesis by norepinephrine, peptides, and other pineal transmitters. Pharmacolgical Reviews 55, 325-95.
70. Smith J. A., Mee T. J. & Barnes J. L. (1977) Elevated melatonin serum concentrations in psychiatric patients treated with chlorpromazine (proceedings). Journal of Pharmacy and Pharmacology 29 (Suppl.), 30P.
71. Smits M. G., Nagtegaal E. E., van der Heijden J., Coenen A. M. & Kerkhof G. A. (2001) Melatonin for chronic sleep onset insomnia in children: A randomized placebo-controlled trial. Journal of Child Neurology 16, 86-92.
72. Suhner A., Schlagenhauf P., Hofer I., Johnson R., Tschopp A. & Steffen R. (2001) Effectiveness and tolerability of melatonin and zolpidem for the alleviation of jet lag. Aviation, Space and Environmental Medicine 72, 638-46.
73. Sutherland E. R., Martin R. J., Ellison M. C. & Kraft M. (2002) Immunomodulatory effects of melatonin in asthma. American Journal of Respiratory and Critical Care Medicine 166, 1055-61.
74. Sutherland E. R., Ellison M. C., Kraft M. & Martin R. J. (2003) Elevated serum melatonin is associated with the nocturnal worsening of asthma. Journal of Allergy and Clinical Immunology 112, 513-17.
75. Voordouw B. C., Euser R., Verdonk R. E., Alberda B. T., de Jong F. H., Drogendijk A. C., Fauser B. C. & Cohen M. (1992) Melatonin and melatonin-progestin combinations alter pituitary-ovarian function in women and can inhibit ovulation. Journal of Clinical Endocrinology and Metabolism 74, 108-17.
76. Waldhauser G., Wieszenbacher G., Zeitlhuber U., Waldhauser M., Frisch H. & Wurtman R. J. (1984) Fall in nocturnal serum melatonin levels during prepuberty and pubescence. Lancet 18, 362-5.
77. Waldhauser F., Lieberman H. R., Lynch H. J., Waldhauser M., Herkner K., Frisch H., Vierhapper H., Waldhausl W., Schemper M., Wurtman R. J. & Crowley W. F. (1987) A pharmacological dose of melatonin increases PRL levels in males without altering those of GH, LH, FSH, TSH, testosterone or cortisol. Neuroendocrinology 46, 125-30.
78. Waldhauser F., Weiszenbacher G., Tatzer E., Gisinger B., Waldhauser M., Schemper M. & Frisch H. (1988) Alterations in nocturnal serum melatonin levels in humans with growth and aging. Journal of Clinical Endocrinology and Metabolism 66, 648-52.
79. Waldhauser F., Boepple P. A., Schemper M., Mansfield M. J. & Crowley W. F., Jr (1991) Serum melatonin in central precocious puberty is lower than in age-matched prepubertal children. Journal of Clinical Endocrinology and Metabolism 73, 793-6.
80. Wang F., Li J., Wu C., Yang J., Xu F. & Zhao Q. (2003) The GABA (A) receptor mediates the hypnotic activity of melatonin in rats. Pharmacology, Biochemistry and Behavior 74, 573-8.
81. Wassmer E., Carter P. F., Quinn E., McLean N., Welsh G., Seri S. & Whitehouse W. P. (2001) Melatonin is useful for recording sleep EEGs: A prospective audit of outcome. Developmental Medicine and Child Neurology 43, 735-8.
82. Wehr T. A., Aeschbach D. & Duncan W. C., Jr (2001) Evidence for a biological dawn and dusk in the human circadian timing system. Journal of Physiology 535, 937-51.
83. Wiggs L. & Stores G. (1996) Severe sleep disturbances and daytime challenging behaviour in children with severe learning disabilities. Journal of Intellectual Disability Research 40, 518-28.
84. Woo M. M., Tai C. J., Kang S. K., Nathwani P. S., Pang S. F. & Leung P. C. (2001) Direct action of melatonin in human granulosa-luteal cells. Journal of Clinical Endocrinology and Metabolism 86, 4789-97.
85. Zhdanova I. V., Wurtman R. J., Lynch H. J., Ives J. R., Dollins A. B., Morabito C., Matheson J. K. & Schomer D. L. (1995) Sleep-inducing effects of low doses of melatonin ingested in the evening. Clinical Pharmacology and Therapeutics 57, 552-8.
86. Zhdanova I. V., Wurtman R. J., Morabito C., Piotrovska V. R. & Lynch H. J. (1996) Effects of low oral doses of melatonin, given 2-4 hours before habitual bedtime, on sleep in normal young humans. Sleep 19, 423-31.
87. Zhdanova I. V., Wurtman R. J. & Wagstaff J. (1999) Effects of a low dose of melatonin on sleep in children with Angelman syndrome. Journal of Pediatric Endocrinology and Metabolism 12, 57-67.